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Background: To determine if testosterone levels are influenced by dopaminergic therapy in Parkinson disease (PD)
patients. Testosterone level has been reported to be low in patients with PD and other neurodegenerative diseases. In
this study, we sought to determine whether dopaminergic therapy (i.e. levodopa and dopamine agonist) influenced
testosterone levels. We used a cohort of consecutive male patients from the INSPECT trial–a multi-center, prospective,
study that primarily investigated the effects of short-term treatment with pramipexole or levodopa on [123I] B-CIT SPECT
imaging in early PD.
Methods: Testosterone levels were drawn on consenting male subjects with early PD who enrolled in the
INSPECT trial at three study visits (baseline, 12 weeks post-treatment, and 8–12 weeks post-washout). Subjects
were randomized to: no treatment, pramipexole (up to 3 mg) or levodopa (up to 600 mg). Testosterone levels
were obtained twice (prior to 10 AM) and averaged for each of three study visits.
Results: Thirty two male patients participated in this sub-study and there were no significant differences in
disease characteristics in the 3 groups at baseline. Twenty-nine patients completed the follow-up visits and were
suitable for analysis. There were statistically significant differences in the change in free testosterone level,
increased in both the levodopa group and pramipexole group but decreased in the untreated group at 12-weeks
post-treatment. There were no significant differences in the changes of UPDRS total or motor scores, although there
was a strong trend toward improvement in motor scores. The testosterone level persisted in its increase only in the
pramipexole group at the end of the washout period.
Conclusion: These preliminary data support the premise that dopaminergic medications do not reduce testosterone
levels in early PD patients.
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There has been mounting evidence suggesting that in-
appropriately low plasma testosterone levels commonly
exist in male patients with Parkinson disease (PD) [1-6].
The relevance and underlying cause of this endocrine
disturbance remain unknown. Additionally, replacement
of testosterone has not to date been proven to signifi-
cantly improve the motor and non-motor symptoms of
these patients, though there have been anecdotal successes* Correspondence: okun@neurology.ufl.edu
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unless otherwise stated.[4-7]. Two main hypotheses have been proposed to
explain the low testosterone levels: the levels are reduced
by dopaminergic medications, or the testosterone level is
a surrogate marker for pathology known to occur in the
hypothalamus and in other relevant regions of the PD
brain [4]. We sought to examine the former hypothesis
that dopaminergics may lower testosterone. In this study
we utilized the INSPECT cohort of early PD subjects.Methods
Consecutive male PD patients (who fulfilled the UK
Parkinson’s Disease Brain Bank Criteria [8]) enrolled in
the INSPECT study had plasma free and total testosteronetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Study design.
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and total) drawn prior to 10 AM during each study visit
as described in a previous study [4]. The levels for each
subject at each study interval were averaged. Three scans-
[123I]ｧ-CIT and SPECT imaging were performed at
baseline, 12 weeks following randomization to treatment
group (levodopa [up to 600 mg/day], pramipexole [up to
3 mg/day], or no treatment), and 8–12 weeks following
medication washout (see Figure 1). Baseline levels and de-
scriptive clinical variables were recorded, and changes
from baseline to 12 weeks post-treatment, and changes
from baseline to 8–12 weeks post washout were compared
between the three groups using analysis of variance
(ANOVA).
The University of Florida Institutional Review Board
(IRB) through the parent INSPECT study approved the
investigation, and each participant provided informed
consent.
Results
Thirty-two consecutive male patients enrolled in the
study and no differences in disease characteristics be-
tween groups were seen at baseline (Table 1). Twenty
nine patients completed the follow-up visits and wereTable 1 Baseline characteristics of subjects in the study
Group N Age PD duration UPDRS
Mean SD Mean SD Mean
Pramipexole 12 68.83 13.13 2.44 1.67 21.92
Levodopa 9 70.33 9.31 2.11 1.45 17.44
NoTreatment 11 60.36 6.55 2.1 1.6 17.91
Legend: UPDRS M- Unified Parkinson Disease Rating Scale Motor Subsection, UPDRS T
level; Total T - total testosterone level.suitable for analysis. Figure 2 shows the mean and 95%
confidence interval of the free testosterone level by time
and group. The free testosterone level increased in
both the levodopa group (change of 5.41 ± 16.18) and
pramipexole group (8.95 ± 13.15), but decreased in
the untreated group (−13.92 ± 23.12) from baseline to
12-week post-treatment. The between group difference
reached a statistical significance of 0.019 with the use of
an ANOVA test on the changes. There were no significant
changes in UPDRS total or motor scores although there
was a trend toward improvement in motor scores in both
treatment groups compared to placebo. The increase in
testosterone level persisted only the pramipexole group
post-washout (see Tables 2 and 3).
Discussion and conclusions
These results suggest that neither levodopa nor pramipexole
decrease testosterone level in early PD. The observation that
the untreated group experienced further lowering of free
testosterone levels lends support to the hypothesis that
testosterone decline in PD may be a result of disease-specific
factors, and that the decline is less likely iatrogenically
induced by dopaminergic medications. It is not entirely clear
why the increase in free testosterone levels persisted in theM UPDRS T Free T Total T
SD Mean SD Mean SD Mean SD
5.62 30.75 8.25 63.69 25.24 386.32 151.73
7.09 25.22 10.51 55.03 18.18 361.06 146.71
8.23 26.09 11.41 89.54 29.88 449.55 134.92
- Unified Parkinson Disease Rating Scale total score. Free T - free testosterone
Figure 2 Mean and 95% confidence interval of the free testosterone level by time and group.
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have been used in the treatment of prolactinoma, because
dopamine is a natural inhibitor of prolactin [9,10]. Prolac-
tin lowers leutenizing hormone (LH) which in turn lowers
testosterone level [11-16]. Thus, dopamine agonists may
theoretically increase testosterone levels by inhibiting pro-
lactin. This point will need further clarification.
Sinhamahapatra and Kirschner in 1971 published a
detailed analysis of the effect of levodopa on testosteroneTable 2 Summary of changes from baseline to 12 weeks
post treatment
Group N Total T UPDRS M UPDRS T
Mean SD Mean SD Mean SD
Pramipexole 10 34.80 87.33 −4.27 6.15 −5.91 7.34
Sinemet 9 −34.17 59.79 −6.11 6.77 −9.11 10.62
NoTreatment 10 21.80 74.71 0.90 6.64 −0.50 8.87
p = 0.12 p = 0.06 p = 0.12
Legend: Total T - total testosterone level. UPDRS M- Unified Parkinson Disease
Rating Scale Motor Subsection; UPDRS T- Unified Parkinson Disease Rating
Scale total score. Free testosterone measured in pg/ml, and total testosterone
in ng/dl.level [17]. They sought in their study to answer the ques-
tion as to whether levodopa stimulated LH production
and Leydig cell activity. They utilized an electron capture
gas liquid chromatographor, an older technique now con-
sidered less accurate when compared to more modern
techniques for measuring testosterone. Seven PD men
staged using an older system devised by Leon were in-
cluded in the analysis . Very high doses of levodopa were
used (2–6 grams/day). There were other methodologicalTable 3 Summary of changes from baseline to the end of
washout period
Group N Total T UPDRS M UPDRS T
Mean SD Mean SD Mean SD
Pramipexole 7 103.79 49.47 0.89 5.62 1.56 5.29
Sinemet 7 −13.21 40.27 1.86 6.54 1.71 7.93
NoTreatment 9 100.78 104.58 0.78 8.63 −0.22 11.39
p = 0.01 p = 0.95 p = 0.88
Legend: Total T - total testosterone level. UPDRS M- Unified Parkinson Disease
Rating Scale Motor Subsection; UPDRS T- Unified Parkinson Disease Rating
Scale total score. Free testosterone measured in pg/ml, and total testosterone
in ng/dl.
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enrolled (>325 ng/ml), and 2/7 PD patients who did not
improve on levodopa. One interesting aspect of their study
was the calculation of testosterone production and metab-
olism, as well as the measurement of LH. The study con-
cluded that levodopa did not have an impact on plasma
testosterone or LH [17]. Despite methodological limitations
this data is supportive of our findings.
We suspect based on our results that the finding of low
testosterone in PD patients is indicative of intrinsic PD
pathology. It is well known that Lewy Body pathology is
present in PD patients at post-mortem examination, and
lesions includes hypothalamic involvement [18-22]. Braak
has shown that this hypothalamic pathology may be
present relatively early in the course of PD [18-21].
We propose this as a plausible explanation for the
low testosterone levels.
There were several limitations in this study that should
be addressed in future investigations. These limitations
included a small sample size, the lack of non-PD controls,
the use of early PD patients, differences between free and
total testosterone levels, and observed changes in testos-
terone level were small and not likely clinically relevant.
There were changes seen between free testosterone and
total testosterone and this highlighted difficulties in labora-
tory measurements. Most experts use a free or bioavailable
testosterone level as the gold standard rather than utilizing
both a free and total testosterone level [23-25]. Despite
these limitations we conclude as did Sinhamahapatra,
that dopaminergics are probably not the cause of low
testosterone in PD. Clinicians should not assume that
low testosterone levels are an effect of PD medica-
tions. There is currently no evidence that checking a
testosterone level prior to dopaminergic therapy will
be clinically useful. We suggest that future research
on this topic should focus on disease related factors as
the potential culprits in the low testosterone PD story, how-
ever a larger study of the effects of medication can confirm
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